The Study Of The Effects Of Dactylorhin B Isolated From Tibetan Herb And Novel Compound FLZ On Neurodegenerative Diseases (Alzheimer's Disease And Parkinson's Disease) And Their Mechanisms

Alzheimer's disease (AD) is a common neurodegenerative disease in aged people; its characteristic is progressive dementia. AD severely affects the patient's cognition, memory, living ability and motion. With the prolongation of world's average life expectancy, the incidence of AD is increasing, so, the treatment of AD is one of the most complicated problems in senile medicine. To study the etiology of AD and developing new drugs is very important in the field of pharmacology. Nowadays, some drugs are used for AD therapy, while these drugs can only ameliorate the dementia symptom for mild AD patients, but are inefficient for moderate or severe AD patients. Because the etiology of AD is still unclear, to develop efficient drugs to prevent or treat AD is facing challenge and opportunity.Parkinson's disease (PD), also called Parkinsonism, is a neurodegenerative disease cased by disturbance of extrapyramid system's function. Its cardinal clinical symptoms include bradykinesia, rigidity, tremor at rest and disturbances in balance. The characteristic pathogenesis of PD is degeneration of dopaminergic neurons in nigra zona compacta and decrease of the neuron-transmitter dopamine content in striatum, which lead to dysfunction of the dopaminergic neurons and relative domination of cholinergic function. All the above alterations finally result in development of dyskinesis. Drugs currently used for PD therapy can only improve clinical symptoms but cannot retard the progress of the disease. Moreover, severe side effects developed in the long-term treatment. New drugs with better curative effects and fewer side effects are urgently needed. Recently, a new concept for pharmacotherapy of PD called neuroprotective strategy has been proposed. Several...